Delaware court lets Zantac lawsuits go ahead, wiping $8B+ from GSK market cap
GSK shares were down more than 9% premarket on Monday after a Delaware court allowed more than 70,000 Zantac-related cases against the drugmaker to go …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
